Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Good Start Genetics Raises $18 Million For Sequencing-Based Testing

This article was originally published in Start Up

Executive Summary

Now with $18 million in hand from a trio of blue chip investors, Good Start Genetics is off to, well, a good start as it readies its panel of preconception genetic disease screening tests for launch into the in vitro fertilization market next year. But ultimately, its goal is clearly to leverage beyond the first set of tests and market.

Related Content

Safeguard Jumps Into Life Science But Leaves Behind Early-Stage Risk
Personalized Medicine In 2010: Welcome To The Establishment
Personalized Medicine In 2010: Welcome To The Establishment
The A-List: 2010's Trend-Shaping Series A Financings
The How And When Of Applying Sequencing To Clinical Diagnostics
Noninvasive Prenatal Diagnostics: How Much Closer to Reality?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts